Cargando…
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
BACKGROUND: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. METHODS: We performed a pooled analysis of treatments after pr...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782547/ https://www.ncbi.nlm.nih.gov/pubmed/33024268 http://dx.doi.org/10.1038/s41416-020-01089-9 |
_version_ | 1783631928251908096 |
---|---|
author | Rossini, Daniele Lonardi, Sara Antoniotti, Carlotta Santini, Daniele Tomasello, Gianluca Ermacora, Paola Germani, Marco Maria Bergamo, Francesca Ricci, Vincenzo Caponnetto, Salvatore Moretto, Roberto Zaniboni, Alberto Pietrantonio, Filippo Buonadonna, Angela Ritorto, Giuliana Masi, Gianluca Latiano, Tiziana Pia Rapisardi, Stefania Falcone, Alfredo Cremolini, Chiara |
author_facet | Rossini, Daniele Lonardi, Sara Antoniotti, Carlotta Santini, Daniele Tomasello, Gianluca Ermacora, Paola Germani, Marco Maria Bergamo, Francesca Ricci, Vincenzo Caponnetto, Salvatore Moretto, Roberto Zaniboni, Alberto Pietrantonio, Filippo Buonadonna, Angela Ritorto, Giuliana Masi, Gianluca Latiano, Tiziana Pia Rapisardi, Stefania Falcone, Alfredo Cremolini, Chiara |
author_sort | Rossini, Daniele |
collection | PubMed |
description | BACKGROUND: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. METHODS: We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction. RESULTS: Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045). CONCLUSIONS: First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS. |
format | Online Article Text |
id | pubmed-7782547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77825472021-10-07 Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO Rossini, Daniele Lonardi, Sara Antoniotti, Carlotta Santini, Daniele Tomasello, Gianluca Ermacora, Paola Germani, Marco Maria Bergamo, Francesca Ricci, Vincenzo Caponnetto, Salvatore Moretto, Roberto Zaniboni, Alberto Pietrantonio, Filippo Buonadonna, Angela Ritorto, Giuliana Masi, Gianluca Latiano, Tiziana Pia Rapisardi, Stefania Falcone, Alfredo Cremolini, Chiara Br J Cancer Article BACKGROUND: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. METHODS: We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction. RESULTS: Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045). CONCLUSIONS: First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS. Nature Publishing Group UK 2020-10-07 2021-01-05 /pmc/articles/PMC7782547/ /pubmed/33024268 http://dx.doi.org/10.1038/s41416-020-01089-9 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/ Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Article Rossini, Daniele Lonardi, Sara Antoniotti, Carlotta Santini, Daniele Tomasello, Gianluca Ermacora, Paola Germani, Marco Maria Bergamo, Francesca Ricci, Vincenzo Caponnetto, Salvatore Moretto, Roberto Zaniboni, Alberto Pietrantonio, Filippo Buonadonna, Angela Ritorto, Giuliana Masi, Gianluca Latiano, Tiziana Pia Rapisardi, Stefania Falcone, Alfredo Cremolini, Chiara Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title_full | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title_fullStr | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title_full_unstemmed | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title_short | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO |
title_sort | treatments after progression to first-line folfoxiri and bevacizumab in metastatic colorectal cancer: a pooled analysis of tribe and tribe2 studies by gono |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782547/ https://www.ncbi.nlm.nih.gov/pubmed/33024268 http://dx.doi.org/10.1038/s41416-020-01089-9 |
work_keys_str_mv | AT rossinidaniele treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT lonardisara treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT antoniotticarlotta treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT santinidaniele treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT tomasellogianluca treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT ermacorapaola treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT germanimarcomaria treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT bergamofrancesca treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT riccivincenzo treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT caponnettosalvatore treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT morettoroberto treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT zanibonialberto treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT pietrantoniofilippo treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT buonadonnaangela treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT ritortogiuliana treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT masigianluca treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT latianotizianapia treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT rapisardistefania treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT falconealfredo treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono AT cremolinichiara treatmentsafterprogressiontofirstlinefolfoxiriandbevacizumabinmetastaticcolorectalcancerapooledanalysisoftribeandtribe2studiesbygono |